Physician profile
Charles Peter Katopes
NPI 1184701377
$2,522.91
in general payments reported to CMS, 2019-2025
19 companies · $982 in 2025
The $982 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $217 · 2024: $1,217 · 2025: $982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,415.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.71 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $208.13 | 2024-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $203.82 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.36 | 2023-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $130.01 | 2024-2025 | |
| Lilly USA, LLC | $121.11 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $118.99 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $117.05 | 2025 | Rezdiffra |
| Pharmacosmos Therapeutics INC. | $90.14 | 2022 | |
| Pfizer INC. | $89.56 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $85.03 | 2023-2025 | Ocaliva |
| Janssen Biotech, INC. | $81.04 | 2022-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $75.72 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $72.06 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $46.29 | 2024-2025 | Zenpep |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $41.06 | 2024 | Zeposia |
| Fresenius Kabi USA, LLC | $19.68 | 2024 | Idacio |
| Astrazeneca Pharmaceuticals LP | $18.40 | 2024 | Andexxa |
| Exact Sciences Corporation | $13.75 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Katopes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.